


In a landmark development for women’s health, Polycystic Ovary Syndrome (PCOS) has officially been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following a global consensus process involving patients, clinicians, researchers, and professional organisations worldwide. The change was formally published in The Lancet in May 2026 after more than a decade of international collaboration.
The change represents far more than a new acronym. It signals a fundamental shift in how we diagnose, and manage one of the most common yet often misunderstood hormonal disorders affecting women.
For many years, experts and patient advocacy groups argued that the term PCOS was misleading.
Firstly, many women diagnosed with PCOS do not have ovarian cysts. Secondly, the name focuses attention on the ovaries when the condition affects multiple systems throughout the body. Research has increasingly shown that hormonal imbalances, insulin resistance, metabolic dysfunction, cardiovascular risk factors, skin health, fertility, and mental wellbeing are all part of the condition’s broader clinical picture.
The new name—Polyendocrine Metabolic Ovarian Syndrome (PMOS)—better reflects the complexity of the condition:
The old terminology often contributed to confusion and frustration for women as they were told they could not have PCOS because they did not have ovarian cysts. Others struggled to understand why they experienced symptoms such as weight gain, fatigue, insulin resistance, acne, fertility challenges, anxiety, or elevated cardiovascular risk when the condition’s name appeared to focus solely on the ovaries.
The new name helps move the conversation beyond reproduction alone. It also and acknowledges that PMOS is a whole-body condition requiring a whole-person approach.
Importantly, the renaming does not change the underlying condition, diagnostic criteria, or current treatment options. But it may lead to earlier diagnosis, greater awareness and more comprehensive care pathways.
One of the most significant aspects of the new name is the inclusion of the word metabolic.
For years, research has shown that insulin resistance is a key driver for many women with PMOS, even among those who are not overweight. Insulin dysregulation can contribute to increased androgen production, irregular ovulation, weight gain, cravings, energy fluctuations, and long-term risks such as type 2 diabetes and cardiovascular disease.
By explicitly recognising the metabolic component, PMOS encourages a broader discussion around nutrition, movement, sleep, stress management, and long-term health outcomes—not just menstrual cycles and fertility.
As our understanding of PMOS evolves, so too does the importance of personalised nutrition.
Nutrition remains one of the most powerful tools we have to support metabolic health, insulin sensitivity, weight management, reproductive function, and overall wellbeing. The challenge however is that PMOS looks different for every woman.
Some may be primarily concerned about fertility. Others may struggle with blood sugar regulation, weight management, acne, irregular periods, fatigue, or digestive issues. This is why generic dietary advice often falls short.
At Positive Nutrition, we have always viewed PCOS as a complex, multifactorial condition influenced by hormonal, metabolic, nutritional, and lifestyle factors. The transition to PMOS reflects the broader, whole-person approach that has long underpinned our work with women experiencing this condition.
If you want support with PMOS get in touch with us to find out more about how we can help or book an appointment with one of our nutrition team.